Cresco Labs Inc. (CRLBF)
CRLBF is quoted over the counter, not listed on an exchange. Cresco Labs Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-16.
Profile
| Field | Value |
|---|---|
| Ticker | CRLBF, quoted over the counter |
| SEC CIK | 0001832928 |
| OTC Markets tier | OTCQX (price source, 2026-11-13) |
| SEC industry code | Medicinal Chemicals & Botanical Products |
| Business address | Chicago, IL |
| Incorporated in | BC |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 40-F 2026-03-06 |
| Cash and burn | $57.9M cash; operating cash flow $18.2M a quarter. | Report 2025-12-31 |
| Shares outstanding | 502,755,064 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Baker Tilly US, LLP, Chicago, Illinois, United States | PCAOB Form AP 2026-04-07 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $655.8M | -$135.4M | $72.9M | $57.9M | $431.2M | $655.8M | 40-F 2026-03-06 |
| FY 2024 2024-12-31 | $724.3M | -$74.4M | $132.5M | $137.6M | $475.3M | $724.3M | 40-F 2026-03-06 |
| FY 2023 2023-12-31 | $770.9M | -$175.5M | $58.6M | $103.4M | $511.5M | $770.9M | 40-F 2025-03-14 |
| FY 2022 2022-12-31 | $842.7M | -$212.0M | $18.7M | $121.5M | $11.0M | $842.7M | 40-F 2024-03-18 |
| FY 2021 2021-12-31 | $821.7M | -$319.6M | $14.5M | $223.5M | $19.9M | $821.7M | 40-F 2023-03-22 |
| FY 2020 2020-12-31 | $476.3M | -$102.2M | -$7.8M | $136.3M | $25.9M | $476.3M | 40-F 2022-04-05 |
| FY 2019 2019-12-31 | $128.5M | -$43.2M | -$25.2M | $49.1M | $550K | $128.5M | 40-F/A 2021-04-29 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest annual report | 40-F | 2026-03-06 |
| Latest quarterly / interim | 6-K | 2026-11-06 |
Source: SEC EDGAR submissions feed, 94 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier